BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 217.5 USD | +1.87% |
|
+4.12% | -15.94% |
| May. 03 | HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating | MT |
| Apr. 30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 53,543 | 37,679 | 35,242 | 39,877 | 37,495 | 31,086 | - | - |
| Enterprise Value (EV) 1 | 51,733 | 41,723 | 37,820 | 40,560 | 43,384 | 34,101 | 31,622 | 28,086 |
| P/E ratio | 9.44 x | 9.87 x | 23.1 x | 13.3 x | 32.5 x | 16.8 x | 14.5 x | 11.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.72 x | 2.8 x | 3.21 x | 3.92 x | 3.81 x | 3.26 x | 3.26 x | 3.14 x |
| EV / Revenue | 3.6 x | 3.1 x | 3.44 x | 3.99 x | 4.41 x | 3.58 x | 3.31 x | 2.84 x |
| EV / EBITDA | 6.41 x | 5.56 x | 9.13 x | 11.2 x | 14.3 x | 10.2 x | 8.73 x | 6.92 x |
| EV / FCF | 7.88 x | 11 x | 11.2 x | 35.5 x | 34.2 x | 14.7 x | 11.2 x | 9.42 x |
| FCF Yield | 12.7% | 9.12% | 8.94% | 2.82% | 2.93% | 6.8% | 8.93% | 10.6% |
| Price to Book | 3.87 x | 3.7 x | 3.26 x | 3.02 x | 2.53 x | 1.86 x | 1.65 x | 1.44 x |
| Nbr of stocks (in thousands) | 180,442 | 153,882 | 146,893 | 144,001 | 144,898 | 145,597 | - | - |
| Reference price 2 | 296.7 | 244.9 | 239.9 | 276.9 | 258.8 | 217.5 | 217.5 | 217.5 |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14,378 | 13,445 | 10,982 | 10,173 | 9,836 | 9,521 | 9,548 | 9,885 |
| EBITDA 1 | 8,070 | 7,504 | 4,144 | 3,618 | 3,040 | 3,347 | 3,623 | 4,061 |
| EBIT 1 | 7,390 | 6,837 | 3,656 | 3,099 | 2,545 | 2,870 | 3,075 | 3,361 |
| Operating Margin | 51.4% | 50.85% | 33.3% | 30.47% | 25.87% | 30.14% | 32.2% | 34% |
| Earnings before Tax (EBT) 1 | 7,126 | 5,048 | 1,745 | 3,592 | 1,297 | 2,257 | 2,784 | 3,383 |
| Net income 1 | 5,888 | 4,001 | 1,556 | 3,047 | 1,161 | 1,896 | 2,211 | 2,642 |
| Net margin | 40.96% | 29.76% | 14.17% | 29.95% | 11.8% | 19.92% | 23.16% | 26.73% |
| EPS 2 | 31.42 | 24.80 | 10.40 | 20.87 | 7.970 | 12.97 | 14.97 | 18.29 |
| Free Cash Flow 1 | 6,564 | 3,805 | 3,382 | 1,144 | 1,270 | 2,319 | 2,825 | 2,981 |
| FCF margin | 45.65% | 28.3% | 30.8% | 11.25% | 12.91% | 24.36% | 29.59% | 30.15% |
| FCF Conversion (EBITDA) | 81.34% | 50.71% | 81.61% | 31.62% | 41.79% | 69.3% | 77.99% | 73.4% |
| FCF Conversion (Net income) | 111.47% | 95.11% | 217.34% | 37.55% | 109.4% | 122.28% | 127.78% | 112.81% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,734 | 2,532 | 2,589 | 2,508 | 2,544 | 2,463 | 2,456 | 2,530 | 2,386 | 2,290 | 2,383 | 2,408 | 2,447 | 2,365 | 2,413 |
| EBITDA 1 | 780.7 | 844.1 | 1,112 | 991 | 792.7 | 674.7 | 797.7 | 853.1 | 697.5 | 795.5 | 956.5 | 981.6 | 1,024 | - | - |
| EBIT 1 | 646 | 708.6 | 976.7 | 870 | 672.9 | 467.5 | 674.2 | 728.1 | 557.4 | 648 | 719.4 | 734.9 | 725.7 | 718.1 | 751.9 |
| Operating Margin | 23.63% | 27.99% | 37.72% | 34.68% | 26.45% | 18.98% | 27.45% | 28.78% | 23.36% | 28.29% | 30.19% | 30.52% | 29.66% | 30.37% | 31.15% |
| Earnings before Tax (EBT) 1 | 405 | 347.4 | 1,270 | 1,371 | 603.8 | 438.3 | 708.1 | -141.2 | 291.6 | 464.8 | 627.3 | 545 | 549.5 | 512.5 | 526.5 |
| Net income 1 | 368.2 | 303.8 | 1,058 | 1,135 | 550.4 | 387.9 | 591.6 | -68.1 | 249.7 | 393.4 | 525.9 | 481.4 | 490.1 | 458 | 488.3 |
| Net margin | 13.47% | 12% | 40.86% | 45.23% | 21.64% | 15.75% | 24.09% | -2.69% | 10.47% | 17.18% | 22.07% | 19.99% | 20.03% | 19.37% | 20.23% |
| EPS 2 | 2.500 | 2.060 | 7.240 | 7.840 | 3.790 | 2.670 | 4.070 | -0.4700 | 1.710 | 2.700 | 3.599 | 3.184 | 3.361 | 3.290 | 3.405 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/22 | 5/3/22 | 7/20/22 | 10/25/22 | 2/15/23 | 4/25/23 | 7/25/23 | 11/8/23 | 2/13/24 | 4/24/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4,044 | 2,578 | 683 | 5,888 | 3,014 | 536 | - |
| Net Cash position 1 | 1,810 | - | - | - | - | - | - | 3,000 |
| Leverage (Debt/EBITDA) | - | 0.5389 x | 0.6221 x | 0.1888 x | 1.937 x | 0.9007 x | 0.1479 x | - |
| Free Cash Flow 1 | 6,564 | 3,805 | 3,382 | 1,144 | 1,270 | 2,319 | 2,825 | 2,981 |
| ROE (net income / shareholders' equity) | 47.7% | 45.2% | 26.6% | 21.2% | 15.2% | 14.3% | 14.6% | 14.5% |
| ROA (Net income/ Total Assets) | 24% | 15.4% | 11.9% | 12.6% | 4.52% | 7.56% | 7.57% | 7.86% |
| Assets 1 | 24,583 | 25,927 | 13,124 | 24,216 | 25,699 | 25,073 | 29,195 | 33,622 |
| Book Value Per Share 2 | 76.60 | 66.20 | 73.50 | 91.70 | 102.0 | 117.0 | 132.0 | 151.0 |
| Cash Flow per Share 2 | 38.00 | 26.20 | 24.30 | 9.480 | 10.60 | 19.70 | 20.10 | 24.40 |
| Capex 1 | 515 | 425 | 258 | 240 | 277 | 292 | 283 | 284 |
| Capex / Sales | 3.58% | 3.16% | 2.35% | 2.36% | 2.82% | 3.07% | 2.96% | 2.87% |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
213.5
USD
Average target price
285.9
USD
Spread / Average Target
+33.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.94% | 31.09B | |
| -3.79% | 87.06B | |
| +1.45% | 40.25B | |
| +52.66% | 24.74B | |
| -14.50% | 15.91B | |
| -9.12% | 11.96B | |
| -14.38% | 11.92B | |
| -42.56% | 11.61B | |
| +4.87% | 8.73B | |
| -4.33% | 8.69B |
- Stock Market
- Equities
- BIIB Stock
- Financials Biogen Inc.
